Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study
Authors' conclusion
OS was safe and effective in improving glycemic control, reducing BW, and alleviating diabetes-related distress and unhealthy eating behaviors in patients with type 2 diabetes mellitus switched from DPP-4i.
Study context
- Population
- Adults with T2D with inadequate glycemic control on DPP-4i transitioning to oral semaglutide (OS); mean age 67.5 ± 12.0 years, 55.9% maleenrolled
- Participants
- 281 adults
- Exposure
- Switch from DPP-4i to oral semaglutide
- Outcome
- Change in HbA1c from V1 to V3
- Follow-up
- Week 40 ± 4
Methodological detailsreal-world, 40-week
- Real-world
- 40-week
Main finding
As reported in the abstract
Change in HbA1c · V1 to V3
OS
- 0.7
mean · ± 0.05 · %
- p for HbA1c decrease
- P < 0.0001
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Values |
|---|---|
| Change in body weight · V1 to V3In-study set | OS mean - 3.6 ± 0.22 kg |
- Change in body weight — p for body weight (BW) decrease
- p < 0.0001
Diabetes Distress Scale (DDS) and Dutch Eating Behaviour Questionnaire (DEBQ) scores
- DDS domain and DEBQ emotional and external eating scores decreased, indicating reduced diabetes-related distress and improved eating behaviours
Safety
- Patients reporting adverse events
- 23.1%
- Hypoglycaemic episodes
- 0
Original publication
Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study. Diabetes Res Clin Pract. Published 6 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →